Maternal Serotonin Reuptake Inhibitor Antidepressants Have Acute Effects on Fetal Heart Rate Variability in Late Gestation

Kayleigh S J Campbell; Abby C Collier; Michael A Irvine; Ursula Brain; Dan W Rurak; Tim F Oberlander; Kenneth I Lim

doi:10.3389/fpsyt.2021.680177

Maternal Serotonin Reuptake Inhibitor Antidepressants Have Acute Effects on Fetal Heart Rate Variability in Late Gestation

Front Psychiatry. 2021 Aug 16:12:680177. doi: 10.3389/fpsyt.2021.680177. eCollection 2021.

Authors

Kayleigh S J Campbell^{1

2}, Abby C Collier³, Michael A Irvine¹, Ursula Brain^{1

4}, Dan W Rurak^{1

2}, Tim F Oberlander^{1

4}, Kenneth I Lim^{1

2}

Affiliations

¹ BC Children's Hospital Research Institute, Vancouver, BC, Canada.
² Department of Obstetrics and Gynaecology, University of British Columbia, Vancouver, BC, Canada.
³ Faculty of Pharmaceutical Sciences, University of British Columbia, Vancouver, BC, Canada.
⁴ Department of Pediatrics, University of British Columbia, Vancouver, BC, Canada.

Abstract

Background: Prenatal exposure to serotonin reuptake inhibitor (SRI) antidepressants increases risk for adverse neurodevelopmental outcomes, yet little is known about whether effects are present before birth. In relation to maternal SRI pharmacokinetics, this study investigated chronic and acute effects of prenatal SRI exposure on third-trimester fetal heart rate variability (HRV), while evaluating confounding effects of maternal depressed mood. Methods: At 36-weeks' gestation, cardiotocograph measures of fetal HR and HRV were obtained from 148 pregnant women [four groups: SRI-Depressed (n = 31), SRI-Non-Depressed (n = 18), Depressed (unmedicated; n = 42), and Control (n = 57)] before, and ~5-h after, typical SRI dose. Maternal plasma drug concentrations were quantified at baseline (pre-dose) and four time-points post-dose. Mixed effects modeling investigated group differences between baseline/pre-dose and post-dose fetal HR outcomes. Post hoc analyses investigated sex differences and dose-dependent SRI effects. Results: Maternal SRI plasma concentrations were lowest during the baseline/pre-dose fetal assessment (trough) and increased to a peak at the post-dose assessment; concentration-time curves varied widely between individuals. No group differences in fetal HR or HRV were observed at baseline/pre-dose; however, following maternal SRI dose, short-term HRV decreased in both SRI-exposed fetal groups. In the SRI-Depressed group, these post-dose decreases were displayed by male fetuses, but not females. Further, episodes of high HRV decreased post-dose relative to baseline, but only among SRI-Non-Depressed group fetuses. Higher maternal SRI doses also predicted a greater number of fetal HR decelerations. Fetuses exposed to unmedicated maternal depressed mood did not differ from Controls. Conclusions: Prenatal SRI exposure had acute post-dose effects on fetal HRV in late gestation, which differed depending on maternal mood response to SRI pharmacotherapy. Importantly, fetal SRI effects were sex-specific among mothers with persistent depressive symptoms, as only male fetuses displayed acute HRV decreases. At trough (pre-dose), chronic fetal SRI effects were not identified; however, concurrent changes in maternal SRI plasma levels suggest that fetal drug exposure is inconsistent. Acute SRI-related changes in fetal HRV may reflect a pharmacologic mechanism, a transient impairment in autonomic functioning, or an early adaption to altered serotonergic signaling, which may differ between males and females. Replication is needed to determine significance with postnatal development.

Keywords: antidepressant pharmacokinetics; fetal heart rate variability; maternal depressed mood; pregnancy; prenatal exposure; serotonin reuptake inhibitor antidepressants; sex differences; third-trimester.